News Feeds

HealthFolk's News section is a health news aggregator with a focus on Nigeria, and Africa as a whole.

[Correspondence] Dyspnoea in the GLOBAL LEADERS trial – Authors' reply

Tags: General

We thank David Martí and Marcelo Sanmartín for their interest in GLOBAL LEADERS.
  • Vranckx P
  • Valgimigli M
  • Juni P
  • et al.
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial.